Related Experiment Video

Updated: May 20, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a

Dermot Phelan1, Paaladinesh Thavendiranathan, Patrick Collier

  • 1Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USA.

Heart (British Cardiac Society)
|July 14, 2012
PubMed

Insights

Aldosterone antagonists (AA) significantly improve ejection fraction (EF) and functional capacity in heart failure patients. These benefits occur regardless of initial symptom severity, suggesting broader use of AA is warranted.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Current guidelines recommend aldosterone antagonists (AA) for patients with moderately severe to severe systolic heart failure (New York Heart Association [NYHA] class III-IV).
  • The efficacy of AA in improving ejection fraction (EF) and functional capacity requires further investigation, particularly concerning baseline NYHA classification.

Purpose of the Study:

  • To determine the efficacy of aldosterone antagonists (AA) in improving ejection fraction (EF) and functional capacity.
  • To assess whether baseline NYHA classification influences the effect of AA on EF and functional capacity.

Main Methods:

  • Meta-analysis of fourteen prospective randomized controlled trials involving 1,575 patients.
  • Data extraction and analysis performed independently by two researchers using MEDLINE and Cochrane Library databases.

Main Results:

  • Aldosterone antagonists (AA) demonstrated a weighted mean improvement in ejection fraction (EF) of 3.2% and in NYHA classification of 0.13 compared to controls (p<0.001).
  • Meta-regression analysis indicated that baseline NYHA classification did not predict improvements in EF (p=0.67) or NYHA status (p=0.18).

Conclusions:

  • Aldosterone antagonists (AA) significantly improve EF and functional class in heart failure patients, independent of baseline functional capacity.
  • These findings support expanding the use of AA beyond current guidelines, suggesting reconsideration of restrictions to NYHA class III-IV patients.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Adrenergic Antagonists: Pharmacological Actions of &#593;-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...